250 related articles for article (PubMed ID: 27795368)
1. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
Yu XQ; Robbie GJ; Wu Y; Esser MT; Jensen K; Schwartz HI; Bellamy T; Hernandez-Illas M; Jafri HS
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795368
[TBL] [Abstract][Full Text] [Related]
2. Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease.
Tkaczyk C; Hamilton MM; Sadowska A; Shi Y; Chang CS; Chowdhury P; Buonapane R; Xiao X; Warrener P; Mediavilla J; Kreiswirth B; Suzich J; Stover CK; Sellman BR
mBio; 2016 Jun; 7(3):. PubMed ID: 27353753
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
[TBL] [Abstract][Full Text] [Related]
5. Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity
Tkaczyk C; Semenova E; Shi YY; Rosenthal K; Oganesyan V; Warrener P; Stover CK; Sellman BR
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150481
[TBL] [Abstract][Full Text] [Related]
6. Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.
Tabor DE; Yu L; Mok H; Tkaczyk C; Sellman BR; Wu Y; Oganesyan V; Slidel T; Jafri H; McCarthy M; Bradford P; Esser MT
Antimicrob Agents Chemother; 2016 Sep; 60(9):5312-21. PubMed ID: 27324766
[TBL] [Abstract][Full Text] [Related]
7. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia.
Sharma-Kuinkel BK; Wu Y; Tabor DE; Mok H; Sellman BR; Jenkins A; Yu L; Jafri HS; Rude TH; Ruffin F; Schell WA; Park LP; Yan Q; Thaden JT; Messina JA; Fowler VG; Esser MT
J Clin Microbiol; 2015 Jan; 53(1):227-36. PubMed ID: 25392350
[TBL] [Abstract][Full Text] [Related]
8. Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.
Tkaczyk C; Kasturirangan S; Minola A; Jones-Nelson O; Gunter V; Shi YY; Rosenthal K; Aleti V; Semenova E; Warrener P; Tabor D; Stover CK; Corti D; Rainey G; Sellman BR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584141
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against
Ruzin A; Wu Y; Yu L; Yu XQ; Tabor DE; Mok H; Tkaczyk C; Jensen K; Bellamy T; Roskos L; Esser MT; Jafri HS
Clin Transl Immunology; 2018; 7(1):e1009. PubMed ID: 29484186
[TBL] [Abstract][Full Text] [Related]
11. An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
Gunale B; Farinola N; Kamat CD; Poonawalla CS; Pisal SS; Dhere RM; Miller C; Kulkarni PS
Lancet Infect Dis; 2024 Jun; 24(6):639-649. PubMed ID: 38408457
[TBL] [Abstract][Full Text] [Related]
12. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
Robbie GJ; Criste R; Dall'acqua WF; Jensen K; Patel NK; Losonsky GA; Griffin MP
Antimicrob Agents Chemother; 2013 Dec; 57(12):6147-53. PubMed ID: 24080653
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-
Peck M; Rothenberg ME; Deng R; Lewin-Koh N; She G; Kamath AV; Carrasco-Triguero M; Saad O; Castro A; Teufel L; Dickerson DS; Leonardelli M; Tavel JA
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910894
[No Abstract] [Full Text] [Related]
14. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.
Weisman LE; Fischer GW; Thackray HM; Johnson KE; Schuman RF; Mandy GT; Stratton BE; Adams KM; Kramer WG; Mond JJ
Int Immunopharmacol; 2009 May; 9(5):639-44. PubMed ID: 19268719
[TBL] [Abstract][Full Text] [Related]
16. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model.
Hua L; Cohen TS; Shi Y; Datta V; Hilliard JJ; Tkaczyk C; Suzich J; Stover CK; Sellman BR
Antimicrob Agents Chemother; 2015 Aug; 59(8):4526-32. PubMed ID: 25987629
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.
Ali SO; Yu XQ; Robbie GJ; Wu Y; Shoemaker K; Yu L; DiGiandomenico A; Keller AE; Anude C; Hernandez-Illas M; Bellamy T; Falloon J; Dubovsky F; Jafri HS
Clin Microbiol Infect; 2019 May; 25(5):629.e1-629.e6. PubMed ID: 30107283
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial.
François B; Mercier E; Gonzalez C; Asehnoune K; Nseir S; Fiancette M; Desachy A; Plantefève G; Meziani F; de Lame PA; Laterre PF;
Intensive Care Med; 2018 Nov; 44(11):1787-1796. PubMed ID: 30343314
[TBL] [Abstract][Full Text] [Related]
19. Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.
Diep BA; Hilliard JJ; Le VT; Tkaczyk C; Le HN; Tran VG; Rao RL; Dip EC; Pereira-Franchi EP; Cha P; Jacobson S; Broome R; Cheng LI; Weiss W; Prokai L; Nguyen V; Stover CK; Sellman BR
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115346
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.
Wu Y; Liu X; Akhgar A; Li JJ; Mok H; Sellman BR; Yu L; Roskos LK; Esser MT; Ruzin A
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29263109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
